Biomarker Discovery & Analysis

Indivumed Services, a Crown Bioscience Company offers an industry-leading oncology biobank and a range of service platforms to advance oncology and immuno-oncology drug discovery and development. They offer a wide range of biobank products to support your research and development in personalized medicine, biomarker validation, drug discovery, and companion diagnostics.

You can now gain access to-

Multi-omics Grade Biospecimens- Complete cancer biospecimen set, including matched normal adjacent tissue, plasma, serum, PBMCs, and urine

Longitudinal Cell-Free Plasma (Liquid Biopsy)- enable the isolation of circulating tumor DNA (ctDNA) from pre- and post-treatment plasma samples

Standard Grade Biospecimens – FFPE samples
Full range of cancer entities, including normal adjacent tissues, normal tissue, post mortem tissue

In addition, Crown Bioscience’s extensive experience and advanced laboratory can help the customers identify, qualify & validate the biomarkers from various biological samples like blood, serum & tissues with the help of multi-parametric flow cytometry, immunohistochemistry, high throughput imaging, ELISA-based cytokine,  chemokine profiling ,PCR & NGS based assays.

The early identification of biomarkers allows clients to de-risk drug development, as well as rescue or repurpose previously unsuccessful drugs through the reinterpretation of clinical trial results.

DMPK Services

DMPK studies play a crucial role in drug discovery for optimizing the drug-like properties of compounds or drug molecules. Crown Bioscience offers these services as part of an integrated drug discovery program or standalone basis, and include cutting-edge LC-MS/MS and HPLC technologies alongside ELISA-based and MSD assays.

Efficacy services

Crown Bioscience offers range of efficacy services to screen oncology, immuno-oncology with the help of comprehensive in-vitro, in-vivo models & databases.

• Oncology
  • In-vitro  screening – 2D & 3D models
  • CDX & PDX Models

• Immuno-oncology
  • Syngeneic Models
  • CDX & Humanized Models

Technologies

Crown Bioscience is constantly involved in developing, evaluating, and utilizing innovative technologies to serve the dynamic needs of preclinical and translational studies. It provides an end-to-end service platform, using the most advanced analysis to generate comprehensive data, utilizing machine intelligence for better-informed decisions.

• OmniScreen™
  • Cost-effective, rapid, and large-scale cancer cell line screening to advance the lead compound to validated candidate

• MuScreen™
  • Fast-track of in-vivo immunotherapy development with large-scale syngeneic and tumor homograft screening

• HuPrime^®
  • 2,500 Highly characterized PDX models translates to 30 Human cancer types (includes rare indications & highly specific molecular targets)

• HuKemia^®
  • Blood cancer PDX models

• HuBase™
  • Platform to browse or search PDX models using Crown’s unique, online curated database

• HuMark™
  • Platform to identify biomarkers to help predict patient clinical response

• HuTrial™
  • Preclinical population studies that help stratify patients for clinical trials

• HuSignature™
  • Platform to identify gene signatures to help predict patient clinical response

• HuGEMM™
  • Immunocompetent chimeric mouse models, engineered to express humanized drug targets such as genes encoding for immune checkpoint proteins